GSK · Pharma and healthcare · one day
GSK (GSK): news on Tuesday 3 November 2026
News from the 24 hours to Tuesday morning, 3 November 2026.
Tone of the day
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage was mostly analyst ratings, with a positive Bernstein view offset by two neutral ratings from other brokers. Some supportive commentary on recent drug successes and further liver disease data added a mild positive lean, while the shares were flat.
What drove it
- analyst ratings
- specialty and hepatitis B progress
- liver disease data
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Wed 28 Oct | +7.0 | 23 |
| Thu 29 Oct | −6.3 | 77 |
| Fri 30 Oct | −3.7 | 21 |
| Sat 31 Oct | +4.0 | 12 |
| Mon 2 Nov | +8.0 | 3 |
| Tue 3 Nov | +2.7 | 6 |
4 stories · 6 headlines · strongest first
Pharma and healthcare on 3 NovemberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| Broker ratings on GSK +2.43 headlines today · 6 in all, since 31 October · Bernstein kept Buy, while Deutsche Bank and Goldman Sachs kept Neutral. | ||
| +6.3 | Broker retains a positive recommendation on the shares. | |
| 0.0 | Analyst keeps a middling stance, neither positive nor negative. | |
| 0.0 | Broker maintains a middling view, no change in outlook. | |
| GSK specialty and hepatitis B outlook +5.71 headline today · A piece asks whether GSK can extend its recent progress in hepatitis B as well as specialty. | ||
| +5.7 | Commentary points to recent successes in specialty medicines and hepatitis B. | |
| Alfasigma presents linerixibat data at liver meeting +3.71 headline today · Alfasigma will present new linerixibat data at AASLD's Liver Meeting. | ||
| +3.7 | Partner presenting further data on GSK-developed liver drug. | |
| GSK shares trade flat near support +0.51 headline today · GSK shares were flat with buyers defending 1,830p. | ||
| +0.5 | Shares steady, holding a price floor without much movement. | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated GSK: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.